Voor zorgverleners

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

What is PRALUENT®?

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

PRALUENT is available as a unique,¥ once-monthly pen

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).